-
1
-
-
67650674658
-
The worldwide overview: New results for systemic adjuvant therapies
-
San Antonio, TX, USA, Dec 13-16
-
Peto R for the Early Breast Cancer Trialists' Collaborative Group The worldwide overview: new results for systemic adjuvant therapies. Presentation at the 30th Annual SABCS, San Antonio, TX, USA, Dec 13-16, 2007.
-
(2007)
Presentation at the 30th Annual SABCS
-
-
Peto, R.1
-
2
-
-
80054100462
-
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) ASCO Ann Meet Proc 2011
-
abstr 507
-
Guarneri V, Frassoldati A, Bottini A, Generali DG, Cagossi K, et al.: Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). ASCO Ann Meet Proc 2011. J Clin Oncol 2011;29(suppl):abstr 507.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Guarneri, V.1
Frassoldati, A.2
Bottini, A.3
Generali, D.G.4
Cagossi, K.5
-
3
-
-
77949884661
-
Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
-
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1124-1130
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
Rugo, H.4
Sledge, G.5
Koehler, M.6
Ellis, C.7
Casey, M.8
Vukelja, S.9
Bischoff, J.10
Baselga, J.11
O'Shaughnessy, J.12
-
4
-
-
82355192663
-
TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer ASCO Ann Meet Proc 2011
-
abstr 505
-
Chang JCN, Mayer IA, Forero-Torres A, Nanda R, Goetz MP, et al.: TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. ASCO Ann Meet Proc 2011. J Clin Oncol 2011;29(suppl):abstr 505.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Jcn, C.1
Mayer, I.A.2
Forero-Torres, A.3
Nanda, R.4
Goetz, M.P.5
-
5
-
-
79952274439
-
Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere')
-
San Antonio, TX, USA, Dec 8-12, Cancer Research abstr S3-2
-
Gianni L, Pienkowski T, Im YH, Roman L, Tseng L-M, Liu M-C, Lluch-Hernandez A, Semiglazov V, Szado T, Ross G: Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). 33rd Annual CTRC-AACR SABCS, San Antonio, TX, USA, Dec 8-12, 2010; Cancer Research 2010;70:abstr S3-2.
-
(2010)
33rd Annual CTRC-AACR SABCS
, vol.70
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.H.3
Roman, L.4
Tseng, L.-M.5
Liu, M.-C.6
Lluch-Hernandez, A.7
Semiglazov, V.8
Szado, T.9
Ross, G.10
-
6
-
-
79952258750
-
First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer
-
San Antonio, TX, USA, Dec 8-12, Cancer Research 2010; 70 abstr S3
-
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M; on Behalf of the NeoALTTO Study Team: First results of the NeoALTTO trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. 33rd Annual CTRC-AACR SABCS, San Antonio, TX, USA, Dec 8-12, 2010; Cancer Research 2010; 70:abstr S3.
-
(2010)
33rd Annual CTRC-AACR SABCS
-
-
Baselga, J.B.1
-
7
-
-
83255175479
-
Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM 4450g/BO21976)
-
Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, Song C, Tong B, Chu YW, Perez EA: Trastuzumab emtansine (T-DM1) vs. trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). Eur J Cancer 2011;47:S330.
-
(2011)
Eur J Cancer
, vol.47
-
-
Hurvitz, S.1
Dirix, L.2
Kocsis, J.3
Gianni, L.4
Lu, J.5
Vinholes, J.6
Song, C.7
Tong, B.8
Chu, Y.W.9
Perez, E.A.10
-
8
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al.: Molecular portraits of human breast tumours. Nature 2000;406:747-52.
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
Van De Rijn, M.4
Jeffrey, S.S.5
Rees, C.A.6
Pollack, J.R.7
Ross, D.T.8
Johnsen, H.9
Akslen, L.A.10
Fluge, O.11
Pergamenschikov, A.12
-
9
-
-
78951482208
-
Deconstructing the molecular portraits of breast cancer
-
Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
-
(2011)
Mol Oncol
, vol.5
, pp. 5-23
-
-
Prat, A.1
Perou, C.M.2
-
10
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1160-7
-
-
Parker, J.S.1
Mullins, M.2
Cheang, M.C.3
Leung, S.4
Voduc, D.5
Vickery, T.6
Davies, S.7
Fauron, C.8
He, X.9
Hu, Z.10
Quackenbush, J.F.11
Stijleman, I.J.12
-
11
-
-
79960980007
-
Strategies for subtypes -Dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
-
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes -dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47.
-
(2011)
Ann Oncol
, vol.22
, pp. 1736-1747
-
-
Goldhirsch, A.1
Wood, W.C.2
Coates, A.S.3
Gelber, R.D.4
Thurlimann, B.5
Senn, H.J.6
-
12
-
-
62449131093
-
Supervised risk predictor of breast cancer based on intrinsic subtypes
-
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1160-7
-
-
Parker, J.S.1
Mullins, M.2
Cheang, M.C.3
Leung, S.4
Voduc, D.5
Vickery, T.6
Davies, S.7
Fauron, C.8
He, X.9
Hu, Z.10
Quackenbush, J.F.11
Stijleman, I.J.12
-
13
-
-
79959288369
-
A supervised risk predictor of breast cancer based on biological subtypes
-
abstr 11008
-
Parker J: A supervised risk predictor of breast cancer based on biological subtypes. ASCO Ann Meet Proc 2008. J Clin Oncol 2008;26(suppl):abstr 11008.
-
(2008)
ASCO Ann Meet Proc 2008. J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
Parker, J.1
-
14
-
-
80052877920
-
Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis ASCO Ann Meet Proc 2011
-
abstr 1028
-
Von Minckwitz G, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, et al.: Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. ASCO Ann Meet Proc 2011. J Clin Oncol 2011; 29(suppl):abstr 1028.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Von Minckwitz, G.1
Kaufmann, M.2
Kuemmel, S.3
Fasching, P.A.4
Eiermann, W.5
-
15
-
-
33745603978
-
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
-
DOI 10.1038/sj.onc.1209415, PII 1209415
-
Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008. (Pubitemid 43990755)
-
(2006)
Oncogene
, vol.25
, Issue.28
, pp. 3994-4008
-
-
Doane, A.S.1
Danso, M.2
Lal, P.3
Donaton, M.4
Zhang, L.5
Hudis, C.6
Gerald, W.L.7
-
16
-
-
19944422061
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
-
DOI 10.1056/NEJMoa041588
-
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al.: A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med 2004;351: 2817-26. (Pubitemid 40051905)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.27
, pp. 2817-2826
-
-
Paik, S.1
Shak, S.2
Tang, G.3
Kim, C.4
Baker, J.5
Cronin, M.6
Baehner, F.L.7
Walker, M.G.8
Watson, D.9
Park, T.10
Hiller, W.11
Fisher, E.R.12
Wickerham, D.L.13
Bryant, J.14
Wolmark, N.15
-
17
-
-
71749091235
-
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays
-
Albain KS, Paik S, van't Veer L: Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009;18(suppl 3):S141-5.
-
(2009)
Breast
, vol.18
, Issue.SUPPL. 3
-
-
Albain, K.S.1
Paik, S.2
Van'T Veer, L.3
-
18
-
-
33744814477
-
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
-
DOI 10.1200/JCO.2005.04.7985
-
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34. (Pubitemid 46622311)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.23
, pp. 3726-3734
-
-
Paik, S.1
Tang, G.2
Shak, S.3
Kim, C.4
Baker, J.5
Kim, W.6
Cronin, M.7
Baehner, F.L.8
Watson, D.9
Bryant, J.10
Costantino, J.P.11
Geyer Jr., C.E.12
Wickerham, D.L.13
Wolmark, N.14
-
19
-
-
77951637777
-
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study
-
Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, et al.: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1829-1834
-
-
Dowsett, M.1
Cuzick, J.2
Wale, C.3
Forbes, J.4
Mallon, E.A.5
Salter, J.6
Quinn, E.7
Dunbier, A.8
Baum, M.9
Buzdar, A.10
Howell, A.11
Bugarini, R.12
-
20
-
-
81155133281
-
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer
-
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, et al.: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-8.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4273-8
-
-
Cuzick, J.1
Dowsett, M.2
Pineda, S.3
Wale, C.4
Salter, J.5
Quinn, E.6
Zabaglo, L.7
Mallon, E.8
Green, A.R.9
Ellis, I.O.10
Howell, A.11
Buzdar, A.U.12
-
21
-
-
79954827812
-
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20
-
Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE Jr, Mamounas EP, Wickerham DL, Wolmark N: Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast cancer Res Treat 2011;127:133-42.
-
(2011)
Breast Cancer Res Treat
, vol.127
, pp. 133-142
-
-
Tang, G.1
Shak, S.2
Paik, S.3
Anderson, S.J.4
Costantino, J.P.5
Geyer Jr., C.E.6
Mamounas, E.P.7
Wickerham, D.L.8
Wolmark, N.9
-
22
-
-
80052418906
-
Additional value and potential use of the 70-gene prognosis signature in nodenegative breast cancer in daily clinical practice
-
Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC: Additional value and potential use of the 70-gene prognosis signature in nodenegative breast cancer in daily clinical practice. Ann Oncol 2009;22:2021-30.
-
(2009)
Ann Oncol
, vol.22
, pp. 2021-2030
-
-
Bueno-De-Mesquita, J.M.1
Sonke, G.S.2
Van De Vijver, M.J.3
Linn, S.C.4
-
23
-
-
36549030796
-
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER)
-
DOI 10.1016/S1470-2045(07)70346-7, PII S1470204507703467
-
Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, et al.: Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8:1079-87. (Pubitemid 350182954)
-
(2007)
Lancet Oncology
, vol.8
, Issue.12
, pp. 1079-1087
-
-
Bueno-De-Mesquita, J.M.1
Van Harten, W.H.2
Retel, V.P.3
Van'T Veer, L.J.4
Van Dam, F.S.5
Karsenberg, K.6
Douma, K.F.7
Van Tinteren, H.8
Peterse, J.L.9
Wesseling, J.10
Wu, T.S.11
Atsma, D.12
Rutgers, E.J.13
Brink, G.14
Floore, A.N.15
Glas, A.M.16
Roumen, R.M.17
Bellot, F.E.18
Van Krimpen, C.19
Rodenhuis, S.20
Van De Vijver, M.J.21
Linn, S.C.22
more..
-
24
-
-
33748693297
-
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
-
DOI 10.1093/jnci/djj329
-
Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, et al.: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92. (Pubitemid 44390989)
-
(2006)
Journal of the National Cancer Institute
, vol.98
, Issue.17
, pp. 1183-1192
-
-
Buyse, M.1
Loi, S.2
Van'T Veer, L.3
Viale, G.4
Delorenzi, M.5
Glas, A.M.6
D'Assignies, M.S.7
Bergh, J.8
Lidereau, R.9
Ellis, P.10
Harris, A.11
Bogaerts, J.12
Therasse, P.13
Floore, A.14
Amakrane, M.15
Piette, F.16
Rutgers, E.17
Sotiriou, C.18
Cardoso, F.19
Piccart, M.J.20
Decker, N.21
Straehle, C.22
more..
-
25
-
-
77950859892
-
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
-
Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van't Veer LJ: The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655-61.
-
(2010)
Breast Cancer Res Treat
, vol.120
, pp. 655-661
-
-
Knauer, M.1
Mook, S.2
Rutgers, E.J.3
Bender, R.A.4
Hauptmann, M.5
Van De Vijver, M.J.6
Koornstra, R.H.7
Bueno-De-Mesquita, J.M.8
Linn, S.C.9
Van'T Veer, L.J.10
-
26
-
-
77950862535
-
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
-
Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van't Veer LJ. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010 21 717-22.
-
(2010)
Ann Oncol
, vol.21
, pp. 717-722
-
-
Mook, S.1
Schmidt, M.K.2
Weigelt, B.3
Kreike, B.4
Eekhout, I.5
Van De Vijver, M.J.6
Glas, A.M.7
Floore, A.8
Rutgers, E.J.9
Van'T Veer, L.J.10
-
27
-
-
74849111553
-
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
-
Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, van't Veer LJ, Rodenhuis S: The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010;119:551-8.
-
(2010)
Breast Cancer Res Treat
, vol.119
, pp. 551-558
-
-
Straver, M.E.1
Glas, A.M.2
Hannemann, J.3
Wesseling, J.4
Van De Vijver, M.J.5
Rutgers, E.J.6
Vrancken Peeters, M.J.7
Van Tinteren, H.8
Van'T Veer, L.J.9
Rodenhuis, S.10
-
28
-
-
18244409687
-
Gene expression profiling predicts clinical outcome of breast cancer
-
DOI 10.1038/415530a
-
Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6. (Pubitemid 34130608)
-
(2002)
Nature
, vol.415
, Issue.6871
, pp. 530-536
-
-
Van'T Veer, L.J.1
Dai, H.2
Van De Vijver, M.J.3
He, Y.D.4
Hart, A.A.M.5
Mao, M.6
Peterse, H.L.7
Van Der Kooy, K.8
Marton, M.J.9
Witteveen, A.T.10
Schreiber, G.J.11
Kerkhoven, R.M.12
Roberts, C.13
Linsley, P.S.14
Bernards, R.15
Friend, S.H.16
-
29
-
-
0037137519
-
A gene-expression signature as a predictor of survival in breast cancer
-
DOI 10.1056/NEJMoa021967
-
Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009. (Pubitemid 35461656)
-
(2002)
New England Journal of Medicine
, vol.347
, Issue.25
, pp. 1999-2009
-
-
Van De Vijver, M.J.1
He, Y.D.2
Van 'T Veer, L.J.3
Dai, H.4
Hart, A.A.M.5
Voskuil, D.W.6
Schreiber, G.J.7
Peterse, J.L.8
Roberts, C.9
Marton, M.J.10
Parrish, M.11
Atsma, D.12
Witteveen, A.13
Glas, A.14
Delahaye, L.15
Van Der Velde, T.16
Bartelink, H.17
Rodenhuis, S.18
Rutgers, E.T.19
Friend, S.H.20
Bernards, R.21
more..
-
30
-
-
34247145491
-
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
-
DOI 10.1200/JCO.2006.07.1522
-
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, et al.: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46. (Pubitemid 46640570)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.10
, pp. 1239-1246
-
-
Loi, S.1
Haibe-Kains, B.2
Desmedt, C.3
Lallemand, F.4
Tutt, A.M.5
Gillet, C.6
Ellis, P.7
Harris, A.8
Bergh, J.9
Foekens, J.A.10
Klijn, J.G.M.11
Larsimont, D.12
Buyse, M.13
Bontempi, G.14
Delorenzi, M.15
Piccart, M.J.16
Sotiriou, C.17
-
31
-
-
77951115122
-
International network of cancer genome projects
-
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, et al.: International network of cancer genome projects. Nature 2010;464:993-8.
-
(2010)
Nature
, vol.464
, pp. 993-998
-
-
Hudson, T.J.1
Anderson, W.2
Artez, A.3
Barker, A.D.4
Bell, C.5
Bernabe, R.R.6
Bhan, M.K.7
Calvo, F.8
Eerola, I.9
Gerhard, D.S.10
Guttmacher, A.11
Guyer, M.12
-
32
-
-
79959838081
-
Integrated genomic analyses of ovarian carcinoma
-
Network TCGA: Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
-
(2011)
Nature
, vol.474
, pp. 609-615
-
-
Tcga, N.1
|